Your activity: 1591 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: [email protected]

Intragastric balloon therapy for weight loss

Intragastric balloon therapy for weight loss
Author:
Robert B Lim, MD, FACS, FASMBS
Section Editor:
Daniel Jones, MD
Deputy Editor:
Wenliang Chen, MD, PhD
Literature review current through: Feb 2022. | This topic last updated: Dec 08, 2021.

INTRODUCTION — More than 1.4 billion adults worldwide are overweight or obese. Such individuals often develop health conditions such as diabetes, hypertension, and heart disease. A modest weight loss of 5 to 10 percent may be sufficient to delay or prevent the onset of diabetes and other obesity-related illnesses [1-3].

However, the availability of safe and effective weight loss therapies is limited [4]. Intragastric balloon therapy is a minimally invasive, temporary method of inducing weight loss. It relies upon a soft saline- or air-filled balloon(s) placed in the stomach to promote the feeling of satiety and restriction (figure 1). The weight loss mechanism of intragastric balloon therapy is restrictive. Any balloon with a volume of 400 mL or greater can induce satiety [5]. Another possible mechanism of action that may also contribute to weight loss is by delaying gastric emptying [6,7]. As with any bariatric procedure, the patient's compliance with lifestyle modifications is essential for achieving and sustaining weight loss during and after therapy.

The indications for intragastric balloon therapy, choices of available balloons, potential adverse effects, and strategies of maintaining weight loss after balloon removal are discussed in this topic. Other methods of achieving weight loss are discussed separately. (See "Obesity in adults: Overview of management" and "Bariatric procedures for the management of severe obesity: Descriptions".)

INDICATIONS — The initial management of obesity is with lifestyle intervention. All patients who would benefit from weight loss should receive counseling on diet, exercise, sleep, and goals for weight loss. (See "Obesity in adults: Overview of management".)

Intragastric balloon therapy is an option for patients with a body mass index (BMI) of greater than 27 kg/m2 in Europe or 30 kg/m2 in the United States (US) who have tried and failed previous attempts at weight management with diet and exercise alone in one of the following situations [4]:

For patients with a BMI of 27 to 35 kg/m2 in Europe or 30 to 35 kg/m2 in the US, intragastric balloon therapy may be used as an early intervention to induce weight loss [8]. Such patients are not eligible for bariatric surgery but could benefit from early intervention in order to prevent or treat obesity-related medical illnesses. (See "Bariatric surgery for management of obesity: Indications and preoperative preparation", section on 'Indications'.)

For patients with a BMI of greater than 40 kg/m2, or 35 kg/m2 with one or more obesity-related medical illnesses, bariatric surgery is the treatment of choice. However, only 1 to 2 percent of eligible patients actually undergo surgery because many consider bariatric surgery to be "too risky" [9]. Thus, for those who are eligible for but refuse to undergo bariatric surgery, or those who lack access to it, intragastric balloon therapy may be used as an alternative intervention to induce weight loss. (See 'Surgical therapies' below.)

For patients with a BMI of greater than 50 kg/m2, intragastric balloon therapy has been proposed as a bridging intervention prior to bariatric surgery. Such patients are at risk of developing anesthesia-related or technical complications due to massive amounts of intra-abdominal fat and hepatomegaly. Preoperative weight loss may decrease the complexity and risk of subsequent bariatric surgery [10].

Of the three scenarios, intragastric balloon therapy is primarily used for those who do not yet meet BMI criteria for surgery. Patients who qualify for bariatric surgery should be encouraged to pursue it, given its superior weight loss efficacy and durability compared with lifestyle changes alone. Because of mixed results, further studies are needed to evaluate intragastric balloon therapy as a bridge therapy to bariatric surgery. (See 'Additional treatment after intragastric balloon therapy' below.)

CONTRAINDICATIONS — Patients seeking intragastric balloon therapy should be screened for potential contraindications with a complete history focusing on gastrointestinal disorders, a physical examination, and radiologic studies (when necessary). Strict adherence to these contraindications helps to limit serious adverse events and maximize patient satisfaction.

Absolute contraindications to intragastric balloon therapy include [11]:

Previous gastric surgery

Coagulation disorders (see "Preoperative assessment of hemostasis")

Bleeding lesion in the upper gastrointestinal tract (see "Causes of upper gastrointestinal bleeding in adults")

Pregnancy or desire to become pregnant

Alcoholism or drug addiction

Severe liver disease (see "Hemostatic abnormalities in patients with liver disease")

Contraindications to endoscopy (see "Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)", section on 'Patient selection')

Relative contraindications to intragastric balloon therapy include [11]:

Previous abdominal surgery

Large hiatal hernia (see "Hiatus hernia")

Inflammatory bowel disease (see "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults" and "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults")

Chronic nonsteroidal anti-inflammatory drug (NSAID) use (see "NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity")

Uncontrolled psychiatric disorders

TYPES OF INTRAGASTRIC BALLOONS — Intragastric balloons differ in material, volume, duration of therapy, adjustability, and method of insertion and removal (table 1).

FDA-approved devices — Currently, there are two US Food and Drug Administration (FDA)-approved intragastric balloon devices:

Orbera — The Orbera balloon is the most commonly used intragastric balloon worldwide. It is made of silicone and placed in the stomach endoscopically and filled with 400 to 700 mL of saline. After residing in the stomach for six months, it is also removed endoscopically.

Obalon — The Obalon system consists of three separate balloons that are inserted by swallowing and filled with gas to 250 mL each via an attached catheter. One balloon is typically inserted per month (up to three); at six months after insertion of the first balloon, all balloons are retrieved endoscopically.

Non-FDA-approved devices — Other devices have not been approved by the FDA and are therefore only marketed outside the United States:

Spatz — The Spatz adjustable balloon system utilizes a saline-filled balloon that can reside in the stomach for up to one year. The volume of the balloon is adjustable. The Spatz balloon is made of silicone and is inserted, adjusted (if necessary), and removed endoscopically. (See 'Additional treatment after intragastric balloon therapy' below.)

Elipse — Elipse is a procedureless gastric balloon made from polyurethane that is swallowed by the patient before it is filled with 550 mL of saline through a thin catheter. After approximately four months, a resorbable material inside the balloon degrades to allow a release valve to open and the balloon to empty. The empty balloon is then excreted naturally. Elipse may be desirable for patients who wish to avoid endoscopy and/or anesthesia [12-14].

EFFICACY OF INTRAGASTRIC BALLOONS

Weight loss

Initial weight loss — Intragastric balloons are capable of producing anywhere from 6 to 15 percent total body weight loss (TBWL), compared with the 1 to 5 percent TBWL produced through lifestyle interventions alone [15].

The degree of weight loss that can be achieved depends upon the balloon system used. Two meta-analyses found greater weight loss with liquid-filled than air-filled balloons [16,17]. A meta-analysis of 55 studies including 6645 Orbera (a liquid-filled balloon) implantations demonstrated a pooled estimate of TBWL of 12.3 (95% CI 7.91-16.73), 13.16 (95% CI 12.37-13.95), and 11.27 percent (95% CI 8.17-14.36) at 3, 6, and 12 months postimplantation [18].

The degree of weight loss that can be achieved also depends upon geographic location. In North America, according to data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), patients lose approximately 10 percent of their total body weight at six months, half of which is during the first 30 days [19]. In Brazil, a study of over 40,000 procedures reported a mean percentage total weight loss of 18.4±2.9 percent [20].

Sustained weight loss — Although intragastric balloons are safe and effective in managing obesity for the short term, they are temporary measures, and weight regain is expected after their removal. In a study of 500 patients who underwent six months of treatment with intragastric balloon therapy, only one-half of the patients maintained 20 percent excess weight loss at one year after balloon removal, and one-quarter of patients kept this weight loss at five years [21]. At 10 years, there is not a difference between balloon therapy and lifestyle changes [22]. Consequently, many patients require additional treatment. (See 'Additional treatment after intragastric balloon therapy' below.)

Improvement in metabolic parameters — Intragastric balloon therapy has been shown to improve metabolic parameters in patients who successfully lose weight [23]. In a meta-analysis of 10 trials and 30 observational studies, there was moderate-quality, but mostly short-term, evidence for improvement in most metabolic parameters after intragastric balloon therapy as opposed to lifestyle intervention [24].

There are no long-term data evaluating patient-important outcomes, such as cardiovascular or overall mortality, although most authorities do not expect intragastric balloon therapy to achieve meaningful and sustained improvements in comorbidities as a monotherapy [15].

COMPARISON WITH OTHER WEIGHT LOSS THERAPIES — Lifestyle interventions and pharmacotherapy usually result in similar weight losses of 2 to 9 percent total body weight [25]. Intragastric balloon therapy can be expected to achieve an 8 to 15 percent total body weight loss (TBWL) in the short term, depending on the type of balloon used [26]. By comparison, bariatric surgery can achieve a TBWL of 13 (adjustable gastric band) to 30 percent (gastric bypass or sleeve gastrectomy) [27]. (See "Obesity in adults: Dietary therapy" and "Obesity in adults: Drug therapy" and "Outcomes of bariatric surgery".)

Lifestyle intervention — The effectiveness of intragastric balloons in inducing weight loss has been demonstrated against lifestyle intervention alone in multiple "pivotal" trials, which largely constituted the bases for their Food and Drug Administration (FDA) approvals [28]:

In a randomized trial of 255 patients comparing Orbera therapy with lifestyle interventions alone, the TBWL among those who completed Orbera for six months (n = 116) was 10.7±6.8 percent, compared with 4.7±5 percent in the control group (n = 99) [29].

In a randomized sham-controlled trial of 387 patients at 15 United States centers (US), treatment with Obalon balloons resulted in greater weight loss (7.1±5.0 percent TBWL) than moderate-intensity lifestyle therapy (3.6±5.1 percent TBWL) [30].

In a randomized trial of 288 patients at seven US centers, treatment with an adjustable balloon (Spatz) resulted in greater weight loss (15 percent TBWL [95% CI 13.9-16.1]) than lifestyle therapy (3.3 percent TBWL [95% CI 2.0-4.6]) at 32 weeks [31]. At six months after balloon removal, 74 percent maintained at least 40 percent of the weight lost at the time of balloon removal.

The REDUCE pivotal trial reported similar results with a dual balloon system [32]. However, that balloon system (Reshape) is no longer marketed.

Pharmacotherapy — There are no trials directly comparing intragastric balloon therapy with pharmacologic methods of weight loss. From data derived from meta-analyses of individual therapies, the extent of weight loss achieved in the short term through intragastric balloon therapy compares favorably with pharmacotherapy [25,26].

However, one study reported that intragastric balloon therapy generally produces a control-subtracted percent TBWL over 6 months of 5.5 to 5.6 percent, which is less than the most efficacious FDA-approved weight loss drug, phentermine and topiramate (Qsymia) [33]. At the recommended dose, Qsymia has a placebo-subtracted percent TBWL at 6 months of approximately 6.6 percent. Direct comparative studies are required to determine if intragastric balloon therapy is more or less effective than weight loss drugs. (See "Obesity in adults: Drug therapy", section on 'Phentermine-topiramate'.)

Surgical therapies — In a retrospective study of over 65,000 patients in the National Patient-Centered Clinical Research Network (PCORnet), one-year mean percent TBWL was 31.2 percent (95% CI 31.1-31.3) for gastric bypass, 25.2 percent (95% CI 25.1-25.4) for sleeve gastrectomy (SG), and 13.7 percent (95% CI 13.3-14.0) for adjustable gastric band; five-year mean percent TBWL was 25.5 percent (95% CI 25.1-25.9) for gastric bypass, 18.8 percent (95% CI 18.0-19.6) for sleeve gastrectomy, and 11.7 percent (95% CI 10.2-13.1) for adjustable gastric band [27]. (See "Bariatric procedures for the management of severe obesity: Descriptions", section on 'Contemporary procedures endorsed by the ASMBS'.)

Given the stark contrast in both weight loss efficacy and durability, intragastric balloon therapy should not be used in lieu of bariatric surgery whenever the latter is appropriate and feasible [34].

ADVERSE EVENTS — The safety profile of intragastric balloons may affect its popularity as a primary weight loss procedure.

In a retrospective analysis of over 1000 procedures performed between 2016 and 2017, 7.2 percent of patients required treatment for dehydration, 2.0 percent required readmission, 1.1 percent required reoperation, and 6.2 percent required intervention within 30 days [19]. In another study of over 145,000 patients, intragastric balloon therapy was associated with a higher adverse event rate than laparoscopic bariatric surgery (odds ratio 1.97, 95% CI 1.10-3.52) due to a significantly higher nonoperative reintervention rate (4.2 versus 1.0 percent) [35].

Common adverse events — At the beginning of intragastric balloon therapy, up to 91 percent of patients will develop some form of gastrointestinal symptoms due to gastric accommodation to the balloon [34]. Typical symptoms include nausea, vomiting, abdominal pain, acid reflux, burping, dyspepsia, and constipation [36].

A variety of medications can be used to control these symptoms. Patients are typically started on a proton pump inhibitor before balloon insertion and prescribed a three- to five-day course of an antiemetic (eg, ondansetron or aprepitant) and an anticholinergic (eg, scopolamine [hyoscine] butylbromide) to be used during the first week of therapy.

Early balloon removal may be necessary if symptoms persist [11,37]. However, very few patients (4 to 7 percent) continue to experience significant gastrointestinal symptoms after the first week of therapy, and even fewer events (<3 percent) required endoscopic reintervention or early balloon removal [34].

Serious adverse events — Serious adverse events are rare, with an incidence of balloon migration, gastric perforation, and mortality of 1.4, 0.1, 0.08 percent, respectively, in one meta-analysis [18]. Serious adverse events may be related to either the balloon or the procedure.

Balloon-related serious adverse events — Serious adverse events that can result from all balloon systems include balloon migration, gastric or esophageal perforation, and gastric ulceration. Serious adverse events that are largely unique to liquid-filled balloons include spontaneous hyperinflation and acute pancreatitis [38].

Balloon migration – Intragastric balloons left in the stomach longer than the intended duration of therapy are at risk of rupturing and migrating into the intestine. While most migrated balloons were excreted successfully, some caused intestinal obstructions [39-41]. Thus, patients should be followed closely to ensure timely balloon removal, which reduces the risk of balloon migration and intestinal obstruction.

Many of the balloons are filled with saline that is dyed blue. If a rupture occurs, the patient's urine may turn blue or green because the spilled dye is absorbed and then excreted by the kidneys. This mechanism warns the patient that the balloon has ruptured, so it can be retrieved before it migrates and causes bowel obstruction.

A multi-balloon platform may have an advantage over a single-balloon design. In a case where one balloon ruptures, the second balloon can prevent migration.

Spontaneous hyperinflation – Hyperinflation involves the spontaneous filling of intragastric balloons with additional air or liquid while inside a patient's stomach, typically resulting in the need for early device removal. The US Food and Drug Administration (FDA) has received over 200 adverse event reports of hyperinflation worldwide since approving the liquid-filled balloons in 2015, with over 99 percent involving Orbera balloons [42].

Acute pancreatitis – Acute pancreatitis may be caused by direct injury from the balloon and distended stomach exerting pressure on the pancreatic parenchyma and/or indirect pancreatic injury through duodenal obstruction. Although acute pancreatitis can develop with any type of balloon, clinically it has been observed mostly with liquid-filled balloons. The FDA has received nearly 30 adverse event reports of acute pancreatitis worldwide since approving the liquid-filled balloons in 2015, with two-thirds involving Orbera balloons [42].

Procedure-related serious adverse events — Most procedure-related serious adverse events occur during balloon removal, including esophageal tear, pneumonia, gastrointestinal bleeding, and esophageal perforation.

Balloon retrieval requires endoscopic equipment specific to each balloon. In general, though, it requires a needle to deflate the balloon and a sturdy grasper or snare to pull the balloon out. The endoscopist performing intragastric balloon insertion and removal must be properly trained to avoid procedure-related complications.

Mortality — The FDA has issued multiple letters to alert health care providers of 18 reported deaths worldwide from 2016 to present in patients with liquid-filled intragastric balloon systems used to treat obesity [42].

According to information from the FDA, 8 of the 18 deaths involved United States patients (five with the Orbera Intragastric Balloon System and three with the ReShape Integrated Dual Balloon System [withdrawn from market]), of which three deaths occurred following gastric perforation, two following pulmonary embolus, one following esophageal perforation, and two are unknown [42].

Although these 18 deaths have been reported since 2016, the incidence rate of death in those who received intragastric balloon therapy is not known. One systematic review published in 2016 showed a mortality rate of 0.05 percent, but that included many of the case series from the early 2000s [43]. A meta-analysis of randomized controlled trials published in 2015 reported a 0 percent mortality rate in 20 studies and almost 1200 patients, but only with a three-month follow-up [16]. The only study that reported its findings on intragastric balloons left in for more than six months reported no mortalities [44], though such practice is generally not recommended. (See 'Balloon-related serious adverse events' above.)

While the mortality may be low, we echo the FDA recommendation that patients be instructed and closely monitored for symptoms of potentially life-threatening complications [42]. (See 'Serious adverse events' above.)

ADDITIONAL TREATMENT AFTER INTRAGASTRIC BALLOON THERAPY — Achieving and maintaining weight loss with any therapy is made difficult by the reduction in energy expenditure that is induced by weight loss. Recidivism, which is regaining of lost weight, is a common problem in treating obesity, including intragastric balloon therapy. (See 'Sustained weight loss' above.)

With continued diet and exercise, 50 percent of the weight loss achieved during intragastric balloon therapy can be maintained for at least one year after balloon removal [39]. Behavior modification strategies should be continued to minimize subsequent weight gain. (See "Obesity in adults: Behavioral therapy".)

Additional measures to sustain or augment weight loss after intragastric balloon therapy include pharmacotherapy, repeat balloon therapy, and bariatric surgery:

Pharmacotherapy — Weight loss medications have been shown to promote weight maintenance in individuals after intragastric balloon therapy [45,46]. The use of weight loss medications is discussed separately. (See "Obesity in adults: Drug therapy".)

Repeat balloon therapy — Intragastric balloon therapy may be repeated in patients who desire further weight loss after a mandatory one-month "balloon holiday." Studies showed that subsequent therapies are as effective as the initial treatment [47,48].

Patients who wish to undergo repeat intragastric balloon therapy should be evaluated individually. Those who were compliant with diet and exercise during the initial treatment are good candidates for retreatment; others are unlikely to benefit from repeat intragastric balloon therapy.

Adjustable balloon system — Multiple studies have demonstrated that 80 to 90 percent of weight loss is achieved during the first three to four months of intragastric balloon therapy, after which time the stomach accommodates and the restrictive effect is partially lost [39]. Thus, an increase in the balloon volume may induce more weight loss. (See 'Spatz' above.)

The Spatz adjustable balloon system permits the volume of the balloon to be adjusted. In a randomized trial, 70 percent of patients underwent adjustment of the balloon volume at four months (halfway point). This resulted in an additional 5.2 percent of total body weight loss (TBWL) between four and eight months. Patients who had the balloon volume adjusted had 3.1 percent greater TBWL than those who did not have any adjustment [31].

Conversely, individuals who experienced balloon intolerance benefited from downward adjustments. In the same trial discussed above, downward adjustment of the balloon volume allowed 75 percent of those patients to complete the 32 weeks of the study rather than undergo early balloon extraction [31]. Still, about 17 percent needed early extraction due to intolerance.

Bariatric surgery — Intragastric balloon therapy has been used in conjunction with bariatric surgery to induce weight loss safely in those with severe obesity. In one study, satisfactory results with Orbera were predictive of a good outcome with subsequent LAP-BAND surgery [49]. Weight loss achieved with presurgical balloon therapy also decreased the risk and complexity of bariatric surgery in individuals with a body mass index of greater than 50 kg/m2 [10]. (See 'Indications' above.)

However, the benefit of balloon therapy as a bridge to bariatric surgery may not be as dramatic as previously thought [50-52]. In a few trials comparing the use of balloon therapy versus control prior to bariatric surgery, although weight loss was greater, preoperative balloon therapy did not prevent postoperative complications and was associated with a 34 percent failure rate and a higher cost [53,54]. Further studies are needed to evaluate intragastric balloon therapy as a bridge therapy to another procedure [34].

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Bariatric surgery".)

SUMMARY AND RECOMMENDATIONS

Mechanism of action – Intragastric balloon therapy entails placing a soft liquid- or gas-filled balloon in the stomach to promote a feeling of satiety and restriction in order to induce weight loss (figure 1). Because its weight loss mechanism is mostly restrictive, its efficacy largely relies upon a patient's adherence to lifestyle changes (ie, diet and exercise). (See 'Introduction' above.)

Indications – Patients with a body mass index (BMI) of greater than 27 kg/m2 in Europe or 30 kg/m2 in the United States (US). Patients must have failed previous attempts at weight management with diet and exercise alone. (See 'Indications' above.)

Contraindications (see 'Contraindications' above):

Absolute – Previous gastric surgery, coagulation disorders, any bleeding lesion in the gastrointestinal tract, pregnancy or desire to become pregnant, alcoholism or drug addiction, severe liver disease, or any contraindication to endoscopy.

Relative – Previous abdominal surgery, large hiatal hernia, inflammatory bowel disease, chronic nonsteroidal anti-inflammatory drug use, or psychiatric disorders.

Balloon types – Intragastric balloons differ in their volume, duration in the stomach, adjustability, and means of insertion and removal (table 1). Orbera and Obalon have been approved by the US Food and Drug Administration (FDA); Spatz and Elipse are marketed outside the US.

Weight loss – Intragastric balloon therapy can achieve 8 to 15 percent total body weight loss (TBWL). By comparison, lifestyle interventions and pharmacotherapy usually result in 2 to 9 percent TBWL, and bariatric surgery can achieve 13 to 30 percent TBWL. (See 'Efficacy of intragastric balloons' above and 'Comparison with other weight loss therapies' above.)

Adverse effects (see 'Adverse events' above):

Common – During the first week of intragastric balloon therapy, a majority of patients will develop gastrointestinal symptoms due to gastric accommodation to the balloon. The combination of a proton pump inhibitor, an antiemetic, and an anticholinergic helps most patients through the first week of therapy, after which time the symptoms greatly diminish.

Serious – Serious adverse events (eg, balloon hyperinflation, migration, acute pancreatitis, or death) can, but rarely does, occur during intragastric balloon therapy and can be minimized by thorough patient education, closely monitoring for complications, timely balloon removal, and adequate training of endoscopists performing the procedure.

Weight regain – With continued diet and exercise, 50 percent of the weight loss achieved during intragastric balloon therapy can be maintained for at least one year after balloon removal. Additional measures to sustain or augment weight loss after intragastric balloon therapy include weight loss medications, repeated balloon therapy after at least a one-month "balloon holiday," balloon volume adjustment (eg, with Spatz), or bariatric surgery. (See 'Additional treatment after intragastric balloon therapy' above.)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Ram Chuttani, MD, who contributed to an earlier version of this topic review.

REFERENCES

  1. Lau DC, Teoh H. Benefits of modest weight loss on the management of type 2 diabetes mellitus. Can J Diabetes 2013; 37:128.
  2. Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children, Centre for Public Health Excellence at NICE (UK), National Collaborating Centre for Primary Care (UK). (Eds), National Institute for Health and Clinical Excellence (UK), London 2006.
  3. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i.
  4. Mathus-Vliegen EM. Endoscopic treatment: the past, the present and the future. Best Pract Res Clin Gastroenterol 2014; 28:685.
  5. Geliebter A. Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 1988; 44:665.
  6. Bonazzi P, Petrelli MD, Lorenzini I, et al. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol Sci 2005; 9:15.
  7. Su HJ, Kao CH, Chen WC, et al. Effect of intragastric balloon on gastric emptying time in humans for weight control. Clin Nucl Med 2013; 38:863.
  8. Martins Fernandes FA Jr, Carvalho GL, Lima DL, et al. Intragastric Balloon for Overweight Patients. JSLS 2016; 20.
  9. Stanford FC, Kyle TK, Claridy MD, et al. The influence of an individual's weight perception on the acceptance of bariatric surgery. Obesity (Silver Spring) 2015; 23:277.
  10. Göttig S, Weiner RA, Daskalakis M. Preoperative weight reduction using the intragastric balloon. Obes Facts 2009; 2 Suppl 1:20.
  11. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg 2008; 18:1611.
  12. Taha O, Abdelaal M, Asklany A, et al. Outcomes of a Swallowable Intragastric Balloon (Elipse™) on 96 Overweight and Obese Patients. Obes Surg 2021; 31:965.
  13. Ienca R, Al Jarallah M, Caballero A, et al. The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients. Obes Surg 2020; 30:3354.
  14. Vantanasiri K, Matar R, Beran A, Jaruvongvanich V. The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis. Obes Surg 2020; 30:3341.
  15. Bazerbachi F, Vargas EJ, Abu Dayyeh BK. Endoscopic Bariatric Therapy: A Guide to the Intragastric Balloon. Am J Gastroenterol 2019; 114:1421.
  16. Saber AA, Shoar S, Almadani MW, et al. Efficacy of First-Time Intragastric Balloon in Weight Loss: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Obes Surg 2017; 27:277.
  17. Bucci M. RNA modifications: Ribosomes get decorated. Nat Chem Biol 2017; 14:1.
  18. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82:425.
  19. Armijo PR, Pokala B, Flores L, et al. Patients undergoing intragastric balloon achieve approximately 50% of their target weight loss in the first month postoperatively: an MBSAQIP analysis. Surg Obes Relat Dis 2019; 15:2060.
  20. Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis 2018; 14:151.
  21. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg 2012; 22:896.
  22. Chan DL, Cruz JR, Mui WL, et al. Outcomes with Intra-gastric Balloon Therapy in BMI < 35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT. Obes Surg 2021; 31:781.
  23. Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc 2010; 71:927.
  24. Popov VB, Ou A, Schulman AR, Thompson CC. The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017; 112:429.
  25. ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy. A pathway to endoscopic bariatric therapies. Surg Obes Relat Dis 2011; 7:672.
  26. Goyal D, Watson RR. Endoscopic Bariatric Therapies. Curr Gastroenterol Rep 2016; 18:26.
  27. Arterburn D, Wellman R, Emiliano A, et al. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study. Ann Intern Med 2018; 169:741.
  28. Moura D, Oliveira J, De Moura EG, et al. Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis 2016; 12:420.
  29. Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond) 2017; 41:427.
  30. Sullivan S, Swain J, Woodman G, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis 2018; 14:1876.
  31. Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet 2021; 398:1965.
  32. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11:874.
  33. Tate CM, Geliebter A. Intragastric Balloon Treatment for Obesity: Review of Recent Studies. Adv Ther 2017; 34:1859.
  34. Telem DA, Ghaferi AA. Gastric Balloons for Weight Loss in 2020. JAMA 2020; 324:2206.
  35. Dang JT, Switzer NJ, Sun WYL, et al. Evaluating the safety of intragastric balloon: An analysis of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Surg Obes Relat Dis 2018; 14:1340.
  36. PMA P140008: FDA Summary of Safety and Effectiveness Data. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008b.pdf (Accessed on January 25, 2016).
  37. Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg 2008; 18:841.
  38. Aljiffry M, Habib R, Kotbi E, et al. Acute Pancreatitis: A Complication of Intragastric Balloon. Surg Laparosc Endosc Percutan Tech 2017; 27:456.
  39. Gaur S, Levy S, Mathus-Vliegen L, Chuttani R. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc 2015; 81:1330.
  40. Yap Kannan R, Nutt MR. Are intra-gastric adjustable balloon system safe? A case series. Int J Surg Case Rep 2013; 4:936.
  41. Roman S, Napoléon B, Mion F, et al. Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg 2004; 14:539.
  42. U.S. Food and Drug Administration (FDA). UPDATE: Potential Risks with Liquid-filled Intragastric Balloons - Letter to Health Care Providers. April 27, 2020. Available at: https://www.fda.gov/medical-devices/letters-health-care-providers/update-potential-risks-liquid-filled-intragastric-balloons-letter-health-care-providers-1 (Accessed on October 14, 2021).
  43. Yorke E, Switzer NJ, Reso A, et al. Intragastric Balloon for Management of Severe Obesity: a Systematic Review. Obes Surg 2016; 26:2248.
  44. Genco A, Maselli R, Frangella F, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc 2015; 29:2339.
  45. Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 2012; 22:565.
  46. Badurdeen D, Hoff AC, Barrichello S, et al. Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon-a Case-Matched Study. Obes Surg 2021; 31:1204.
  47. Alfredo G, Roberta M, Massimiliano C, et al. Long-term multiple intragastric balloon treatment--a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study. Surg Obes Relat Dis 2014; 10:307.
  48. Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg 2010; 20:1496.
  49. Genco A, Lorenzo M, Baglio G, et al. Does the intragastric balloon have a predictive role in subsequent LAP-BAND(®) surgery? Italian multicenter study results at 5-year follow-up. Surg Obes Relat Dis 2014; 10:474.
  50. Leeman MF, Ward C, Duxbury M, et al. The intra-gastric balloon for pre-operative weight loss in bariatric surgery: is it worthwhile? Obes Surg 2013; 23:1262.
  51. Banks J, Abouelazayem M, Kaur V, et al. Routine Intra-gastric Balloon Insertion in the Management of 'Super-Super-Obese' Patients: an Obituary? Obes Surg 2021; 31:2319.
  52. Ashrafian H, Monnich M, Braby TS, et al. Intragastric balloon outcomes in super-obesity: a 16-year city center hospital series. Surg Obes Relat Dis 2018; 14:1691.
  53. Vicente Martin C, Rabago Torre LR, Castillo Herrera LA, et al. Preoperative intragastric balloon in morbid obesity is unable to decrease early postoperative morbidity of bariatric surgery (sleeve gastrectomy and gastric bypass): a clinical assay. Surg Endosc 2020; 34:2519.
  54. Coffin B, Maunoury V, Pattou F, et al. Impact of Intragastric Balloon Before Laparoscopic Gastric Bypass on Patients with Super Obesity: a Randomized Multicenter Study. Obes Surg 2017; 27:902.
Topic 106357 Version 9.0

References

1 : Benefits of modest weight loss on the management of type 2 diabetes mellitus.

2 : Benefits of modest weight loss on the management of type 2 diabetes mellitus.

3 : Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

4 : Endoscopic treatment: the past, the present and the future.

5 : Gastric distension and gastric capacity in relation to food intake in humans.

6 : Gastric emptying and intragastric balloon in obese patients.

7 : Effect of intragastric balloon on gastric emptying time in humans for weight control.

8 : Intragastric Balloon for Overweight Patients.

9 : The influence of an individual's weight perception on the acceptance of bariatric surgery.

10 : Preoperative weight reduction using the intragastric balloon.

11 : Evidence-based review of the Bioenterics intragastric balloon for weight loss.

12 : Outcomes of a Swallowable Intragastric Balloon (Elipse™) on 96 Overweight and Obese Patients.

13 : The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients.

14 : The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis.

15 : Endoscopic Bariatric Therapy: A Guide to the Intragastric Balloon.

16 : Efficacy of First-Time Intragastric Balloon in Weight Loss: a Systematic Review and Meta-analysis of Randomized Controlled Trials.

17 : RNA modifications: Ribosomes get decorated.

18 : ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.

19 : Patients undergoing intragastric balloon achieve approximately 50% of their target weight loss in the first month postoperatively: an MBSAQIP analysis.

20 : Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases.

21 : 500 intragastric balloons: what happens 5 years thereafter?

22 : Outcomes with Intra-gastric Balloon Therapy in BMI< 35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT.

23 : Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients.

24 : The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis.

25 : A pathway to endoscopic bariatric therapies.

26 : Endoscopic Bariatric Therapies.

27 : Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study.

28 : Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials.

29 : Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial.

30 : Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss.

31 : Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.

32 : The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity.

33 : Intragastric Balloon Treatment for Obesity: Review of Recent Studies.

34 : Gastric Balloons for Weight Loss in 2020.

35 : Evaluating the safety of intragastric balloon: An analysis of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program.

36 : Evaluating the safety of intragastric balloon: An analysis of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program.

37 : Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis.

38 : Acute Pancreatitis: A Complication of Intragastric Balloon.

39 : Balancing risk and reward: a critical review of the intragastric balloon for weight loss.

40 : Are intra-gastric adjustable balloon system safe? A case series.

41 : Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy.

42 : Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy.

43 : Intragastric Balloon for Management of Severe Obesity: a Systematic Review.

44 : Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months.

45 : Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity.

46 : Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon-a Case-Matched Study.

47 : Long-term multiple intragastric balloon treatment--a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study.

48 : Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients.

49 : Does the intragastric balloon have a predictive role in subsequent LAP-BAND(®) surgery? Italian multicenter study results at 5-year follow-up.

50 : The intra-gastric balloon for pre-operative weight loss in bariatric surgery: is it worthwhile?

51 : Routine Intra-gastric Balloon Insertion in the Management of 'Super-Super-Obese' Patients: an Obituary?

52 : Intragastric balloon outcomes in super-obesity: a 16-year city center hospital series.

53 : Preoperative intragastric balloon in morbid obesity is unable to decrease early postoperative morbidity of bariatric surgery (sleeve gastrectomy and gastric bypass): a clinical assay.

54 : Impact of Intragastric Balloon Before Laparoscopic Gastric Bypass on Patients with Super Obesity: a Randomized Multicenter Study.